Supplementary Table S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Supplementary Table S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

<p>Supplementary Table S4. Mutations status of patients with disease progression on BTKis</p>

Сохранить в:

Библиографические подробности
Главный автор:	Anfal Alsadhan (15907475) (author)
Другие авторы:	Jonathan Chen (15907478) (author), Erika M. Gaglione (15032498) (author), Chingiz Underbayev (15907481) (author), Pamela L. Tuma (15907484) (author), Xin Tian (15907487) (author), Lita A. Freeman (15907490) (author), Sivasubramanian Baskar (15907493) (author), Pia Nierman (15907496) (author), Susan Soto (15907499) (author), Andy Itsara (15907502) (author), Inhye E. Ahn (15032501) (author), Clare Sun (14953020) (author), Elena Bibikova (15907505) (author), Tanja Nicole Hartmann (15907508) (author), Maissa Mhibik (15907511) (author), Adrian Wiestner (15907514) (author)
Опубликовано:	2025
Предметы:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Immuno-oncology Cell Signaling Cell adhesion Protein tyrosine kinases Drug Resistance Hematological Cancers Leukemias Lymphomas Immunology Immunomodulation
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

Supplementary Table S10 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
по: Anfal Alsadhan (15907475)
Опубликовано: (2025)

Supplementary Table S5 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
по: Anfal Alsadhan (15907475)
Опубликовано: (2025)

Supplementary Table S6 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
по: Anfal Alsadhan (15907475)
Опубликовано: (2025)

Supplementary Table S7 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
по: Anfal Alsadhan (15907475)
Опубликовано: (2025)

Supplementary Table S8 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
по: Anfal Alsadhan (15907475)
Опубликовано: (2025)

Supplementary Table S9 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
по: Anfal Alsadhan (15907475)
Опубликовано: (2025)

Table S9 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
по: Zhihang Chen (17315678)
Опубликовано: (2025)

Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC.docx
по: Xinhang Gu (22686224)
Опубликовано: (2025)

Table S1 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
по: Ruth Flümann (15123900)
Опубликовано: (2025)

Table S2 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
по: Ruth Flümann (15123900)
Опубликовано: (2025)

Table S3 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
по: Ruth Flümann (15123900)
Опубликовано: (2025)

Table S4 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
по: Ruth Flümann (15123900)
Опубликовано: (2025)

Table S5 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
по: Ruth Flümann (15123900)
Опубликовано: (2025)

Table S6 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
по: Ruth Flümann (15123900)
Опубликовано: (2025)

Table S1 from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8<sup>+</sup> T Cells
по: Snehanshu Chowdhury (14957031)
Опубликовано: (2025)

Figure S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
по: Upendra Kumar Soni (15051683)
Опубликовано: (2025)

Figure S2 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
по: Upendra Kumar Soni (15051683)
Опубликовано: (2025)

Figure S3 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
по: Upendra Kumar Soni (15051683)
Опубликовано: (2025)

Figure S4 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
по: Upendra Kumar Soni (15051683)
Опубликовано: (2025)

Figure S5 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
по: Upendra Kumar Soni (15051683)
Опубликовано: (2025)

Figure S6 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
по: Upendra Kumar Soni (15051683)
Опубликовано: (2025)

Supplementary Data File S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
по: Upendra Kumar Soni (15051683)
Опубликовано: (2025)

Supplementary Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy
по: Ti Wen (15130158)
Опубликовано: (2025)

Supplementary Table S1 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer
по: Nan Ding (15321526)
Опубликовано: (2025)

Supplementary Table S2 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer
по: Nan Ding (15321526)
Опубликовано: (2025)

Filamin A KO and S2152A KI reduce KSHV de novo infection of cell-free virions.
по: Xiaojuan Li (351842)
Опубликовано: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
по: Erika Y. Faraoni (14844897)
Опубликовано: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
по: Erika Y. Faraoni (14844897)
Опубликовано: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
по: Erika Y. Faraoni (14844897)
Опубликовано: (2025)

Supplementary Tables from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
по: Francesco Maura (15022226)
Опубликовано: (2025)

Figure 1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
по: Ernesto Gargiulo (15134961)
Опубликовано: (2025)

Figure 2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
по: Ernesto Gargiulo (15134961)
Опубликовано: (2025)

Figure 3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
по: Ernesto Gargiulo (15134961)
Опубликовано: (2025)

Figure 4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
по: Ernesto Gargiulo (15134961)
Опубликовано: (2025)

Figure 5 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
по: Ernesto Gargiulo (15134961)
Опубликовано: (2025)

Figure 6 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
по: Ernesto Gargiulo (15134961)
Опубликовано: (2025)

Figure 7 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
по: Ernesto Gargiulo (15134961)
Опубликовано: (2025)

Supplementary Table S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
по: Jonathan M.J. Derry (16648337)
Опубликовано: (2025)

Supplementary Table S2 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
по: Jonathan M.J. Derry (16648337)
Опубликовано: (2025)

Supplementary Table S3 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
по: Jonathan M.J. Derry (16648337)
Опубликовано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_jatk60ejbfcnhsco9khtjc5v2q